Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday

Key Points

• Pacific Biosciences will report Q1 2026 results after the market closes on Thursday, May 7 at 4:30 PM ET, with analysts forecasting EPS of ($0.17) and revenue of about $39.98 million.
• The stock opened at $1.47 and is down roughly 7%, and analysts have a consensus rating of Reduce with an average target price of $1.67 and recent cuts such as Barclays lowering its target to $1.00.
• Insiders have sold 729,711 shares in the last 90 days, and the company shows strained profitability (ROE -326%, net margin -341%) despite strong liquidity (current ratio 5.15, quick ratio 4.47).

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $39.9810 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 326.43% and a negative net margin of 341.47%.The firm had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Pacific Biosciences of California Stock Down 7.0%

Shares of NASDAQ:PACB opened at $1.47 on Thursday. The stock's 50-day moving average price is $1.48 and its two-hundred day moving average price is $1.83. The company has a current ratio of 5.15, a quick ratio of 4.47 and a debt-to-equity ratio of 120.65. Pacific Biosciences of California has a 12-month low of $0.85 and a 12-month high of $2.73. The firm has a market cap of $456.42 million, a price-to-earnings ratio of -0.80 and a beta of 2.33.

Analyst Ratings Changes

PACB has been the topic of a number of research analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Pacific Biosciences of California in a research note on Tuesday, April 21st. Zacks Research lowered Pacific Biosciences of California from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 20th. Finally, Barclays reduced their price target on Pacific Biosciences of California from $1.50 to $1.00 and set an "underweight" rating for the company in a report on Tuesday, April 14th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $1.67.

Insider Transactions at Pacific Biosciences of California

In other news, insider Michele Farmer sold 35,215 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.58, for a total transaction of $55,639.70. Following the completion of the transaction, the insider owned 234,044 shares of the company's stock, valued at approximately $369,789.52. The trade was a 13.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christian O. Henry sold 140,874 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.63, for a total value of $229,624.62. Following the completion of the sale, the insider owned 2,673,500 shares in the company, valued at approximately $4,357,805. This represents a 5.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 729,711 shares of company stock worth $1,161,951. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Pacific Biosciences of California

Large investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp acquired a new stake in Pacific Biosciences of California in the 4th quarter valued at approximately $34,000. Zacks Investment Management bought a new stake in shares of Pacific Biosciences of California during the 3rd quarter worth $25,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Pacific Biosciences of California by 47.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 6,695 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Pacific Biosciences of California during the 4th quarter worth $40,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Pacific Biosciences of California by 891.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 22,776 shares of the biotechnology company's stock worth $29,000 after buying an additional 20,478 shares during the period.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company's proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.